Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 158-162

  Lefort, Bruno ^a,b,c   Saheb, Samir ^d   Bruckert, Eric ^d   Giraud, Christine ^f   Hequet, Olivier ^e   Hankard, Régis ^a,b,c  

^a CHRU de Tours   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Aorta; Atherosclerosis; Hypercholesterolemia

Indexed keywords

LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADOLESCENT; AORTA RECONSTRUCTION; AORTA STENOSIS; AORTA SURGERY; AORTIC ROOT ATHEROMA; APHERESIS; ARTICLE; ATHEROMA; CHILD; CLINICAL ARTICLE; CORONARY ARTERY; DISEASE COURSE; ECHOCARDIOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPOPROTEIN APHERESIS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL MORTALITY; ADULT; AORTA; BLOOD; COMPLICATION; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; PLAQUE, ATHEROSCLEROTIC; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; SURGERY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AORTA; BLOOD COMPONENT REMOVAL; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921277711     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.007     Document Type: Article

References (20)

1. Goldstein J.L., Brown M.S. The LDL receptor locus and the genetics of familial hypercholesterolemia. Ann. Rev. Genet. 1979, 13:259-289.
2. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
3. Naoumova R.P., Thompson G.R., Soutar A.K. Current management of severe homozygous hypercholesterolemias. Curr. Opin. Lipidol. 2004, 15:413-422.
4. Thompsen J., Thompson P.D. Asystematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
5. Kroon A.A., Van't Hof M.A., Demacker P.N.M., Stalenhoef A.F.H. The rebound of lipoproteins after LDL apheresis. Kinetics and estimation of mean lipoproteins levels. Atherosclerosis 2000, 152:519-526.
6. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., Mandry P., Marais A.D., Matthews S., Neuwirth C., Pottle A., le Roux C., Scullard D., Tyler C., Watkins S. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
7. Borberg H. 26 years of LDL-apheresis: a review of experience. Transfus. Apher. Sci. 2009, 41:49-59.
8. Graesdal A., Bogsrud M.P., Holven K.B., Nenseter M.S., Narverud I., Langslet G., Brekke M., Retterstøl K., Arnesen K.E., Ose L. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J.Clin. Lipidol. 2012, 6:331-339.
9. Hudgins L., Kleinman B., Scheuer A., White S., Gordon B.R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 2008, 102:1199-1204.
10. Makino H., Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther. Apher. Dial. 2003, 7:397-401.
11. Kolansky D., Cuchel M., Clark B., Paridon S., McCrindle B.W., Wiegers S.E., Araujo L., Vohra Y., Defesche J.C., Wilson J.M., Rader D.J. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am. J. Cardiol. 2008, 102:1438-1443.
12. Coker M., Ucar S., Simsek D., Darcan S., Bak M., Can S. Low-density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia. Ther. Apher. Dialysis 2009, 13(2):121-128.
13. Stefanutti C., Lanti A., Di Giacomo S., Mareri M., De Lorenzo F., Landolfo A., Isacchi G. Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfus. Apher. Sci. 2004, 31:3-10.
14. Palcoux J.B., Atassi-Dumont M., Lefevre P., Hequet O., Schlienger J.L., Brignon P., Roussel B. Low-density lipoprotein in children with familial hypercholesterolemia: follow-up to 21 years. Ther. Apher. Dial. 2008, 2(3):195-201.
15. Lefort B., Giraud C., Saulnier J.-P., Bott L., Gambert C., Sosner P., Hankard R. Traitement d'une hypercholestérolémie familiale homozygote par LDL-aphérèses chez un enfant de 4 ans et 6 mois. Arch. Pediatr. 2009, 16:1554-1558.
16. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., Wiegman A., Santos R.D., Watts G.F., Parhofer K.G., Hovingh G.K., Kovanen P.T., Boileau C., Averna M., Borén J., Bruckert E., Catapano A.L., Kuivenhoven J.A., Pajukanta P., Ray K., Stalenhoef A.F., Stroes E., Taskinen M.R., Tybjærg-Hansen A. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European atherosclerosis society. Eur. Heart J. 2013, 34(45):3478-3490a.
17. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223(2):262-268.
18. Cuchel M., Bloedon L., Szapary P., Kolansky D.M., Wolfe M.L., Sarkis A., Millar J.S., Ikewaki K., Siegelman E.S., Gregg R.E., Rader D.J. Inhibition of microsomal triglyceride transfert protein in familial hypercholesterolemia. N.Engl. J. Med. 2007, 356:148-156.
19. Kastelein J., Wedel M., Baker B., Su J., Bradley J.D., Yu R.Z., Chuang E., Graham M.J., Crooke R.M. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114:1729-1735.
20. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., Lachmann R.H., Gaudet D., Tan J.L., Chasan-Taber S., Tribble D.L., Flaim J.D., Crooke S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375(9719):998-1006.